Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
We haven't written up this one. CNBC World has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
